Q1 2026 earnings call recap: raised revenue growth guidance, Omnipod 5 Libre 3 Plus integration, margins, risks & Q2 headwind—read now.

Insulet (NASDAQ:PODD) reported what executives described as a “strong start” to fiscal 2026, posting double-digit revenue ...

U.S. growth of 28% was supported by strong type 2 momentum, though results were tempered by higher-than-normal Q1 seasonality ...

In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with ...

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide ...

Insulet’s latest earnings call carried an upbeat tone, with management emphasizing powerful revenue growth, expanding margins, and a fast-advancing product pipeline. While executives acknowledged ...

Insulet enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 ...

Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on ...

The FDA says nearly 30 serious injuries, including cases of diabetic ketoacidosis, have been linked to recalled Omnipod 5 insulin delivery pods. The recall covers 49 lots with possible internal tubing ...

Insulet reported revenue of $761.7 million for the first quarter of 2026, an increase of 33.9% over the prior year. Total Omnipod revenue was $758.4 million, up 36.9%.

Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.